BioAlliance Pharma gets Swiss MA for Loramyc

BioAlliance Pharma SA, a French company dedicated to the treatment and supportive care of cancer and AIDS patients, says that its drug Loramyc (miconazole) has obtained Marketing Authorization in Switzerland for the treatment of oropharyngeal candidiasis in immunocompromized patients (mainly cancer and AIDS patients with oral opportunistic infections).

'This approval represents an important milestone for Loramyc which is now registered in 12 countries in Europe, including Switzerland. This step will thus reinforce Loramyc opportunity for a European commercial agreement for which we are actively seeking a suitable partner involved in the supportive care field,, said Dominique Costantini, chief executive of BioAlliance Pharma.  'Loramyc's  value has also recently been strengthened by the US Food and Drug Administration acceptance of its New Drug Application,' he added.

Loramyc is already available in four European countries and is being commercialized in the UK, Germany and Denmark by SpeBio (a joint venture founded by BioAlliance with SpePharm in order to sell the product throughout Europe). "The SpeBio team is committed to making the product available to private-practice and hospital-based oncologists, radiotherapists and infectious disease specialists," stated Jean-François Labbe, chief executive of SpeBio last year. "The product has received a very warm welcome, since it fulfils an unmet medical need in the field of oropharyngeal candidiasis in immunocompromized patients," he noted.